Search - tctmd.com

Displaying 1 - 15 of 15

Sort: Relevancy | Date

News Daily News

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Michael O'Riordan

October 10, 2025

News Daily News

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Yael L. Maxwell

August 18, 2025

News Conference News THT 2025

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

Todd Neale

February 12, 2025

News Daily News

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

L.A. McKeown

December 13, 2024

News Daily News

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

Todd Neale

August 15, 2024

News Daily News

Schoolwide Intervention May Improve Obesity Outcomes Over Time

Yael L. Maxwell

July 29, 2024

News Daily News

Childhood Risk Factors Predict Later CVD Risk

L.A. McKeown

June 28, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

L.A. McKeown

December 01, 2023

News Daily News

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

L.A. McKeown

March 24, 2023

News Daily News

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

Michael O'Riordan

December 07, 2022

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Daily News

AHA: Advice on Lifestyle, Risk Factor Modification to Cut A-fib Events

Yael L. Maxwell

March 13, 2020

News Daily News

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Michael O'Riordan

June 14, 2016

News Daily News

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Michael O'Riordan

June 14, 2016

Advertisement

High Aerobic Fitness Linked to Less Chronic Disease in Later Life

Prevention Must Be Prioritized in Heart Failure Care: HFSA/ASPC

Tirzepatide Helps in HFpEF Across Spectrum of Obesity Severity

FINEARTS-HF Analysis Supports Finerenone’s Value in HFpEF With Obesity

Tirzepatide Provides Sustained BP Reduction in Overweight Adults

Schoolwide Intervention May Improve Obesity Outcomes Over Time

Childhood Risk Factors Predict Later CVD Risk

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Oral GLP-1 Drug Danuglipron to Move Forward, but With Tweaks to Dose

Study Debunks Obesity Paradox in HF, Encourages BMI Alternatives

Large Review Plumbs Possibilities, Pointlessness of Antioxidant Supplements

November 2021 News Roundup

AHA: Advice on Lifestyle, Risk Factor Modification to Cut A-fib Events

Liraglutide Leaps Over FDA Safety Hurdle, With Cardiovascular Mortality Reduction to Boot: LEADER

Estudio LEADER: Liraglutide se Salta la Valla de Seguridad de la FDA al Confirmarse un Descenso de la Mortalidad Cardiovascular

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content